Amneal Pharmaceuticals (AMRX): By Most Measures, A Fundamentally Undervalued Company -LSB

6 Min Read

Office notebook with text written note I FEEL UNDERPREMISED - I feel underappreciated at work when hard work and achievements go unnoticed or unrecognized

aria j/iStock via Getty Images

Investment overview

I last covered Amneal Pharmaceuticals (NYSE:AMRX) to search Alpha in a post published in March 2022. I gave the stock a “Buy” rating – at the time, Amneal’s stock was trading at $4 per share, and although it had sunk to $1.3 per

Share This Article
Leave a comment
error: Content is protected !!